Recent studies have shown that alveolar macrophages (AM) are able to release leukotrienes (LTs). Since cigarette smoking inhibits the cyclooxygenase pathway of arachidonic acid metabolism in the AM, we evaluated the LT production by AM from smokers and nonsmokers. AM from nonsmokers, those from smokers showed a 80-90% reduction of 5-HETE and LTB4 synthesis (P < 0.05 to P < 0.001 according to stimulatory conditions). This defective lipoxygenase metabolite production in AM from smokers was observed over a wide range of stimuli concentrations and incubation times; AM from smokers also had lower levels of intracellular (esterified) 5-HETE than nonsmokers' AM. We also studied blood polymorphonuclear leukocytes (PMNL) and no difference in the synthesis of 5-lipoxygenase products in these cells was noticed between smokers and nonsmokers. These data show that cigarette smoking causes a profound inhibition of the 5-lipoxygenase pathway in AM but not in blood PMNL.
Introduction
In the study of lung diseases related to tobacco smoking, special attention has been given to smoking-induced alterations in the morphology and metabolism of alveolar macrophages (AMs)l (1) (2) (3) (4) . The AM, as a phagocytic cell, plays a major role in lung defense mechanisms (5) . Because of its ability to release an array of biologically active molecules, including chemotactic factors, complement components, platelet activating factor (6, 7) , and the recently described leukotriene (LT) B4 (8, 9) , the AM is considered to be an important regulator of inflammatory reactions in the lung (7) .
Leukotrienes (LTs) constitute a newly recognized family of metabolites ofarachidonic acid (10) , with very potent biological properties: LTC4, LTD4, and LTE4 cause both vasoconstriction and bronchoconstriction (11) , and LTB4 is an effective chemotactic factor for polymorphonuclear leukocytes (PMNL) in vitro (12) . In addition, LTB4 causes PMNL to adhere to vascular endothelium and migrate into extravascular tissues in vivo (13) . LTB4 is generated by neutrophils (14) (15) (16) , monocytes (17, 18) , and AM (8, 9) . Its synthesis is initiated by a variety of inflammatory stimuli including phagocytosis (19) and chemotactic substances (20) . These observations suggest a role for LTB4 in inflammation. The capacity of AM to synthesize this potent chemotactic substance and consequently, to recruit PMNL to a site of inflammation, may be an important defense mechanism in the lung.
Because cigarette smoking inhibits the cyclooxygenase-related metabolism of arachidonic acid in the AM (21, 22) and is associated with an increased incidence of infectious diseases in the lung (23, 24) , we undertook a comparative study of LTB4 production by AM in smokers and nonsmokers. For comparison, we also studied the 5-lipoxygenase products synthesis in blood PMNL from smokers and nonsmokers.
Methods
Subjects. 35 subjects volunteered for this study: 16 nonsmokers, 7 males/ 9 females, with a mean age of 27.4±1.8 yr (mean±SEM); and 19 smokers, 9 males/ 10 females, 28.4±1.5 yr. In the nonsmokers' group, one subject was an exsmoker who had quit 3 yr before the study. Smokers consumed 20 cigarettes or more a day and had smoked for at least 3 yr (13.3±2.1 pack-year [1 pack-year = one pack of cigarettes each day for 1 yr, or the equivalent]). None of the subjects smoked marijuana, and all were free of respiratory symptoms suggestive of asthma. None had symptoms of cold, nor had taken any medication for one month before this study. After having given informed consent, the subjects underwent pulmonary function tests (volumes, flows, and diffusion capacity), blood sampling, and bronchoalveolar lavage (BAL). Blood sampling and BAL were performed in the morning, and smokers were asked to refrain from smoking after midnight before testing. cosatetraenoic acid; 1 5-HETE, 1 5S-hydroxy-5,8, 11,1 3-Z,Z,Z,E)-eicosatetraenoic acid; HPLC, high performance liquid chromatography; LT, leukotriene; LTB4, 5S, 12R-dihydroxy-6,8, 10, 14-(Z,E,E,Z)-eicosatetraenoic acid; LTC4, 5S-hydroxy-6R-S-glutathionyl-7,9,11,14-(E,E,Z,Z)-eicosatetraenoic acid; LTD4, 5S-hydroxy-6R-S-cysteinylglycyl-7,9,1 1,14-(E,E,Z,Z)-eicosatetraenoic acid; LTE4, 5S-hydroxy-6R-S-cysteinyl-7,9,11,14-(E,E,Z,Z)-eicosatetraenoic acid; PGB2, prostaglandin B2; PMNL, polymorphonuclear leukocyte. UV, ultraviolet.
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Lidocaine (Astra Scientific International, Inc., Santa Clara, CA) and BAL was carried out by instilling aliquots of 20-60 ml of sterile 0.9% saline solution into a segmental or subsegmental bronchus of the right middle lobe through a fiberoptic bronchoscope and by aspirating the fluid gently with a syringe (25) . The fluid recovered was kept on ice until it was centrifuged (250 g, 10 min, 4C). Cells were resuspended at concentrations of0.8 to 4 X 106 cells/ml in Dulbecco's phosphate-buffered saline solution (PBS) without Ca"+ and Mg". Cell viability, measured by Trypan Blue exclusion, was always higher than 90%. Differential cell counts were performed both on Wright-Giemsa and nonspecific esterase-stained cytocentrifuged preparations.
Blood samples (30 ml) were collected in EDTA and centrifuged (200 g, 15 min, room temperature). PMNL were obtained as described previously by successive dextran sedimentation, NH4Cl lysis, and centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ) cushions (14) . The PMNL were finally resuspended at concentrations ranging from 7 to 12 X 106 cells/ml in PBS (Ca"+ and Mg"+ free). PMNL suspensions were 98% pure and the platelet contamination determined on contrast phase microscope was <1 platelet/leukocyte.
Incubation procedures. vol) containing 200 ng of PGB2 and saved for HPLC analysis of the lipoxygenase products released by AM. The cells were resuspended in 1 ml of PBS (20C) and centrifuged at 250 g for 15 min; the supernatant was discarded and the pellet was treated with 100 Ml of NaOH 2 N and 400 Ml of methanol. After 15 min at room temperature the reaction mixture was neutralized by addition of 100 Ml acetic acid 2 N and diluted with I ml of PBS containing 200 ng of PGB2. The samples were centrifuged to remove any particulate material and analyzed by HPLC as described above. Using this procedure for hydrolysis of 5-hydroxy-eicosatetraenoic acid (5-HETE), the release of 5-HETE from cellular lipids in human PMNL is complete within 15 min.
Statistical analysis. Blood sampling, BAL, cell incubations, and lipoxygenase product analysis were performed in pairs (nonsmoker and smoker) for all experiments but two. Results are expressed as mean±SEM. Data were analyzed using the unpaired t test, except for concentration and time response data, which were compared with a two-way variance analysis.
Results
Pulmonary function tests and BAL. Statistically, smokers and nonsmokers had similar lung volumes and forced expiratory volume in 1 s, but the diffusing capacity for carbon monoxide was lower in the smoker group, P < 0.05. Lavage from smokers differed from those of nonsmokers in having: (a) a greater total cell count, (b) a higher percentage of AM, and (c) a lower percentage of lymphocytes (P < 0.001 for all three parameters) (Table I) . Moreover, smokers' AM were larger, brown in color, and filled with dark inclusions. No significant blood contamination to the BAL was found; only a few erythrocytes were seen in some cell preparations, and platelets were not detectable.
Synthesis of5-lipoxygenase products in AMand PMNL. Fig.   1 shows a typical profile of lipoxygenase-derived arachidonic acid metabolites after incubation of 3.2 X 106 AM with 10 1M [1 -4C] arachidonic acid and 2 ,M ionophore A23 187. Peaks for LTB4 and 5-HETE were clearly evident as the two major metabolites. As expected in incubations with [1-'4C]arachidonic acid, both 5-HETE and LTB4 were radiolabeled. Under all incubation conditions tested, the peptido-LTs, LTC4, LTD4, and LTE4, the w-hydroxy-LTB4, the w-carboxy-LTB4, and the 15-lipoxygenase product, 15-HETE, were undetectable. The products of the nonenzymatic hydrolysis of LTA4, i.e., the A6-trans-LTB4, A6-trans-12-epi-LTB4, and the 5,6-dihydroxy-eicosatetraenoic acids (5,6-DiHETEs) were formed in small quantities (each <5% of the amount of LTB4) and for this reason were seldom measurable. When AM suspensions were incubated for 5 min at 37°C with 0.2% ethanol in the absence of stimulatory substances, 5-HETE and LTB4 were undetectable in the incubation media. Fig. 2 shows a typical profile of arachidonic acid metabolites released by 6.8 X 106 PMNL stimulated with 2 MM ionophore A23 187. Peaks for LTB4 and 5-HETE were again evident, but in contrast to the AM, the PMNL produced measurable quantities of LTC4, w-hydroxy-LTB4, w-carboxy-LTB4, and, in incubation with arachidonic acid, 15-HETE. The PMNL also formed the A6-trans-LTB4, A6-trans-12-epi-LTB4, and the 5,6-DiHETEs. Effects ofcigarette smoking on the synthesis ofLTB4 and 5-HETE in AM and PMNL. Fig. 3 
Discussion
In the present study arachidonic acid metabolites were analyzed using a reverse-phase HPLC system developed recently in our laboratory (16) . The procedure used does not involve extraction, concentration, or derivatization; the sample needs only be denatured, centrifuged to remove particulate matter, and acidified before injection. Because of the simplicity of the sample preparation procedure, loss and deterioration of arachidonic acid metabolites are minimal, and recoveries exceed 90% calculated from the amounts of tritium-labeled LTB4 and LTC4 (carrierfree) injected (16) . Our results on the metabolism of arachidonic acid by suspensions of AM are in excellent agreement with those of Martin et al. (9) obtained under comparable experimental conditions. Their analysis of lipoxygenase products included an extraction of the incubation medium on octadecylsilyl silica followed by an HPLC analysis using a different reverse-phase HPLC system. They found LTB4, 5-HETE, and small amounts of A6-trans-LTB4 and A6-trans-1 2-epi-LTB4, but no peptido-LTs. Studying adherent AM, Fels et al. (8) demonstrated the release of LTB4 by AM stimulated with A23 187 using HPLC techniques, whereas Damon et al. (26) and MacDermot et al. (27) identified LTD4 and LTB4, respectively, using mass spectrometry. The synthesis of 5-lipoxygenase and 1 5-lipoxygenase products by blood PMNL has been investigated in detail previously (14, 16, 28) , and the profile of products reported in the present study is in excellent agreement with these reports.
Except for the 12S-hydroxy-5,8, 10-heptadecatrienoic acid (HHT), cyclooxygenase products are not detectable by UV photometry at the wavelengths used in this study (229 and 280 nm) for the analysis of lipoxygenase products. In the HPLC system used, prostaglandins and thromboxane B2 elute between 2 and 8 min; radiolabeled metabolites were not evident in this area of the chromatograms of both AM and PMNL [I-'4Clarachidonic acid metabolites ( Fig. 1 Table  I and Fig. 3 ) 5-lipoxygenase product synthesis; furthermore, any significant participation on their part should be accompanied by co-OH-LTB4 production (Fig. 2) (30-31) , a metabolite not found in alveolar cell suspensions in this study. The findings, in BAL from smokers, of an increased number of cells, increased percent of AM, decreased percent of lymphocytes and the morphologic changes of AM, were similar to those already reported (1-4, 7) .
The main goal of this study was to compare the capacity of smokers' and nonsmokers' AM to synthesize LTB4. A defective synthesis of 5-lipoxygenase products was found among AM from smokers. This was observed in all stimulatory conditions studied, over a wide stimulus concentration range and various incubation times. Moreover, measurements of intracellular lipoxygenase metabolites indicated that differences in the metabolism of arachidonic acid through the 5-lipoxygenase pathway in smokers' and nonsmokers' AM were observable not only at the level of the products released but also at the level of the intracellular reacylated 5-HETE. The esterification of 5-HETE has been shown in PMNL and macrophages previously (32, 33) . It was also observed that dihydroxy derivatives ofarachidonic acid (such as LTB4) were not subject to reacylation in cellular lipids (33) in agreement with the present study. Martin et al. (9) , who also included smokers and nonsmokers in their study, did not find any difference in LTB4 synthesis by AM between both groups. However, since the number of subjects investigated was small (four smokers, two nonsmokers) and experiments were not carried out in pairs (i.e., smoker vs. nonsmoker), their study does not provide conclusive data on this particular point. In contrast to the AM we did not find any effect of smoking on 5-lipoxygenase product synthesis in blood PMNL (Table III) .
The present finding of altered 5-lipoxygenase product formation in smokers' AM is analogous to the previous reports that cigarette smoking inhibits prostaglandins and thromboxane synthesis in AM (21, 22) . In one of these studies (21) , it was proposed that decreased prostaglandin and thromboxane synthesis in smokers' AM was caused by a defect at the level of phospholipid hydrolysis. The mechanism that leads to the inhibition of 5-lipoxygenase product synthesis in cigarette smokers' AM remains unknown. The decreased 5-HETE and LTB4 production observed, even in the presence of exogenous arachidonic acid, suggests a defect at the level of the dioxygenation reaction, rather than at the level of arachidonic acid release, LTA4 hydrolase activity or product reacylation.
Since LTB4 is a potent chemotactic agent for blood phagocytes (12) and AM are able to release LTB4 on appropriate stimulation (27) , a decreased production of LTB4 by AM may impair their ability to regulate inflammatory responses in the lung. Smokers are known to suffer from more frequent infectious lung diseases than are nonsmokers (23, 24) . Such a predisposition to infection may be related, in part, to defective AM function. Further research is needed to delineate the pathophysiologic consequences of the altered 5-lipoxygenase product synthesis among smokers' AM.
